Sanofi and Regeneron Receive CHMP Positive Opinion for KevzaraA to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Paris, France and Tarrytown, New York - April 24, 2017 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of Kevzara , recommending its approval for use in adult patients with moderately to severely active rheumatoid arthritis. Kevzara is an investigational human monoclonal antibody directed against the IL-6 receptor.
http://ift.tt/2pUVyot
No comments:
Post a Comment